Association Between Cerebral Small Vessel Disease and Plasma Levels of LDL Cholesterol and Homocysteine: Implications for Cognitive Function

Overview

Journal J Med Biochem

Specialty Biochemistry

Date 2024 Dec 23

PMID 39712503

Authors

Yan Cheng

Lichao Li

Yafei Lv

Long Zhang

Wenhua Chen

Gongda Xu

Affiliations

Soon will be listed here.

Abstract

Background: Investigate the correlation between low-density lipoprotein (LDL) cholesterol, homocysteine and cognitive function in patients with cerebral small vessel disease (CSVD).

Methods: 240 patients with CSVD confirmed by head MRI in the Department of Neurology from January 2020 to December 2023 were retrospectively included in the study. All the patients had complete blood biochemical examination, and their cognitive function was evaluated by Montreal Cognitive Assessment Scale (MoCA), and after correcting for the factor of years of education, the patients were divided into a group of normal cognition (MoCA 26, 70 patients) and a group of cognitive function (MoCA 26, 70 patients) according to the scores. After correcting for the factor of years of education, the patients were divided into the normal cognitive function group (70 cases with MoCA 26) and the cognitive dysfunction group (170 cases with MoCA <26) according to their scores. The general information of the two groups and the patients' cognitive function characteristics, including visuospatial and executive ability, naming, attention and calculation, language, abstraction, delayed memory, and orientation, were compared, and the independent influences on the occurrence of cognitive dysfunction in patients with CSVD were analyzed by two-category multifactorial logistic regression.

Results: Compared with the group with normal cognitive function, the cognitive dysfunction group had lower years of education and higher homocysteine, and the differences were statistically significant (P < 0.05). Compared with the group with normal cognitive functioning, the cognitive dysfunction group had lower MoCA total scores, lower visuospatial and executive ability, naming, attention and calculation, language, abstraction, delayed memory, and orientation scores, and the differences were statistically significant (P < 0.05). Two-category multifactorial logistic regression analysis showed that low-density lipoprotein cholesterol (OR=2.756, 95% CI: 0.673-0.938, P=0.012) and homocysteine (OR=1.859, 95% CI: 1.024-1.324, P=0.016) were the independent factors influencing cognitive dysfunction in CSVD patients. The lower the risk of cognitive impairment in CSVD patients, the higher the plasma LDL cholesterol and homocysteine levels, the higher the risk of cognitive impairment in CSVD patients.

Conclusions: Plasma LDL cholesterol and homocysteine levels are associated with and may be predictors of cognitive dysfunction in patients with CSVD.

References

Wang R, Laveskog A, Laukka E, Kalpouzos G, Backman L, Fratiglioni L . MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia. Neurology. 2018; 91(16):e1487-e1497. PMC: 6202944. DOI: 10.1212/WNL.0000000000006355. View

Perla-Kajan J, Twardowski T, Jakubowski H . Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007; 32(4):561-72. DOI: 10.1007/s00726-006-0432-9. View

Georgakis M, Malik R, Anderson C, Parhofer K, Hopewell J, Dichgans M . Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. Brain. 2020; 143(2):597-610. PMC: 7009571. DOI: 10.1093/brain/awz413. View

Wang T, Sun Z, Shao L, Xu X, Liu Y, Qin M . Diagnostic Values of Serum Levels of Homocysteine and Uric Acid for Predicting Vascular Mild Cognitive Impairment in Patients with Cerebral Small Vessel Disease. Med Sci Monit. 2017; 23:2217-2225. PMC: 5436427. DOI: 10.12659/msm.901652. View

Tang H, Wang Y, Cheng A, Wang A, Xu J, Zhang C . Association between Low-Density Lipoprotein Cholesterol Levels and Proximal Single Subcortical Infarction in Comparison with Distal Single Subcortical Infarction. J Stroke Cerebrovasc Dis. 2020; 29(11):105198. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105198. View

Chen Y, Hu M, Gong H . Correlation analysis between the LDL-C in serum and the onset of transient ischemic attack caused by CSVD. Exp Ther Med. 2017; 14(2):1119-1125. PMC: 5526171. DOI: 10.3892/etm.2017.4583. View

Luo M, Ji H, Zhou X, Liang J, Zou T . Correlation of homocysteine metabolic enzymes gene polymorphism and mild cognitive impairment in the Xinjiang Uygur population. Med Sci Monit. 2015; 21:326-32. PMC: 4316859. DOI: 10.12659/MSM.893226. View

Kim J . Role of Blood Lipid Levels and Lipid-Lowering Therapy in Stroke Patients with Different Levels of Cerebral Artery Diseases: Reconsidering Recent Stroke Guidelines. J Stroke. 2021; 23(2):149-161. PMC: 8189863. DOI: 10.5853/jos.2021.01249. View

Skrobot O, Black S, Chen C, DeCarli C, Erkinjuntti T, Ford G . Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2017; 14(3):280-292. DOI: 10.1016/j.jalz.2017.09.007. View

10.

Wang C, Chen Z, Zhang T, Liu J, Chen S, Liu S . Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med. 2014; 25(6):538-44. DOI: 10.1016/j.ejim.2014.04.011. View

11.

Kang S, Yoo H, Cheon B, Park Y, Kim S, Ham H . Distinct effects of cholesterol profile components on amyloid and vascular burdens. Alzheimers Res Ther. 2023; 15(1):197. PMC: 10636929. DOI: 10.1186/s13195-023-01342-2. View

12.

Sachdev P . Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(7):1152-61. DOI: 10.1016/j.pnpbp.2005.06.026. View

13.

Zhu S, Wei X, Yang X, Huang Z, Chang Z, Xie F . Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment. Aging Dis. 2019; 10(4):834-846. PMC: 6675532. DOI: 10.14336/AD.2019.0304. View

14.

An X, Li C . Analysis of risk factors for vascular cognitive impairment in patients with cerebral infarction. Cell Biochem Biophys. 2014; 71(2):673-7. DOI: 10.1007/s12013-014-0246-4. View

15.

Xin J, Huang X, Pan X, Lin L, Sun M, Liu C . Risk Factors for Aphasia in Cerebral Small Vessel Diseases. Curr Neurovasc Res. 2019; 16(2):107-114. DOI: 10.2174/1567202616666190227202638. View

16.

Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M . LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke. 2008; 40(2):382-8. DOI: 10.1161/STROKEAHA.108.529537. View

17.

Jakubowski H . Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999; 13(15):2277-83. View

18.

Zhao Y, Zhou Y, Zhou H, Gong X, Luo Z, Li J . Low-density lipoprotein cholesterol, statin therapy, and cerebral microbleeds: The CIRCLE study. Neuroimage Clin. 2023; 39:103502. PMC: 10474226. DOI: 10.1016/j.nicl.2023.103502. View

19.

Feng C, Bai X, Xu Y, Hua T, Huang J, Liu X . Hyperhomocysteinemia associates with small vessel disease more closely than large vessel disease. Int J Med Sci. 2013; 10(4):408-12. PMC: 3590600. DOI: 10.7150/ijms.5272. View

20.

Amarenco P, Benavente O, Goldstein L, Callahan 3rd A, Sillesen H, Hennerici M . Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009; 40(4):1405-9. DOI: 10.1161/STROKEAHA.108.534107. View